- 01Tirzepatide is one molecule; the label it is sold under decides what it is approved for
Mounjaro and Zepbound hold the same drug in the same strengths. Mounjaro's label covers type 2 diabetes and heart risk in type 2 diabetes 8; Zepbound's covers weight management and obstructive sleep apnea with obesity 7. Insurance usually follows the label, so the same medicine can be covered under one name and refused under the other. Compounded tirzepatide sits outside both labels and has had no FDA review 10. Results in fatty liver and heart failure come from trials, not from any label 11 13, so they show what the drug can do in a study and carry no approval for that use.
Tirzepatide is a once-weekly injection that acts on two gut-hormone receptors, GIP and GLP-1, and in its main trial adults without diabetes lost an average 15% to 21% of their body weight over 72 weeks 1. Mounjaro and Zepbound are this one drug under two labels, and the label, not the pen, decides what it is approved for, what insurance tends to pay for, and why a person without diabetes on Mounjaro is using it off-label.
What tirzepatide is and how it works
Tirzepatide is a lab-made peptide, a chain of 39 amino acids, that switches on the receptors for two incretins, gut hormones released after a meal that tell the pancreas to put out insulin. It acts on both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), where semaglutide acts on GLP-1 alone. A fatty side chain binds it to albumin, the main blood protein, giving a half-life of about 5 days (the time for half a dose to clear). Levels peak 8 to 72 hours after an injection and settle after about 4 weeks of weekly doses 8.
How a weekly tirzepatide shot lowers blood sugar and weight
Mounjaro vs Zepbound: one drug, two labels
Eli Lilly sells tirzepatide under two brand names in the same strengths and forms. A health plan may pay for Mounjaro in type 2 diabetes and refuse Zepbound for weight, because coverage usually follows the label.
| Brand | FDA-approved for | First approved | Forms |
|---|---|---|---|
| Mounjaro | Blood sugar in type 2 diabetes in adults, and in children 10 and older (added December 2025); lower risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk of them (added August 2026) 8 | May 2022 | Weekly single-dose pen or vial, or a four-dose KwikPen or vial |
| Zepbound | Weight management in adults with obesity, or overweight with a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity (added December 2024) 7 | November 2023 | Weekly single-dose pen or vial, or a four-dose KwikPen or vial |
How much weight people lose on tirzepatide
| Trial | Who took part | What happened |
|---|---|---|
| SURMOUNT-1, 72 weeks 1 | 2,539 adults with obesity or overweight, no diabetes | Average weight loss 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo |
| SURMOUNT-2, 72 weeks 7 | Adults with obesity or overweight and type 2 diabetes | 12.8% on 10 mg and 14.7% on 15 mg, against 3.2% on placebo |
| SURMOUNT-3, 72 weeks 15 | 579 adults who had first lost at least 5% with 12 weeks of intensive diet and exercise | A further 18.4% lost on tirzepatide, against a 2.5% gain on placebo |
| SURMOUNT-5, 72 weeks 2 | 751 adults with obesity, no diabetes | 20.2% on tirzepatide against 13.7% on semaglutide |
| SURMOUNT-4, 52 weeks after a 36-week start 3 | 670 adults who had already lost about 21% on tirzepatide | Staying on it: a further 5.5% lost. Switching to placebo: weight up 14.0% from week 36, ending 9.9% below the start |
People with type 2 diabetes lose less, as SURMOUNT-2 against SURMOUNT-1 shows 7 1. Averages also hide a wide spread. In SURMOUNT-1, 85 to 91% of people on tirzepatide lost at least 5% of their weight, against 35% on placebo, and half or more of those on 10 or 15 mg lost at least 20% 1. That still leaves roughly 1 in 10 people on the top dose losing less than 5%, and no test predicts in advance who they will be.
You may also see 22.5% quoted for the 15 mg arm. Both come from the SURMOUNT-1 paper: 20.9% counts everyone assigned to 15 mg, including people who stopped, and 22.5% only those who kept taking it 1. The lower number sits closer to real life; the retatrutide guide calls this split "one trial, two honest numbers".
Beyond weight: blood sugar, sleep apnea, heart and liver
| Use | Approved or trial only | Trial and result |
|---|---|---|
| Blood sugar in type 2 diabetes | Mounjaro label | SURPASS-2, people on metformin, 40 weeks: A1C (the 3-month average of blood sugar) fell 2.01, 2.24 and 2.30 percentage points on 5, 10 and 15 mg, against 1.86 on semaglutide 1 mg 4 |
| Heart attack and stroke in type 2 diabetes | Mounjaro label (August 2026) | SURPASS-CVOT, 13,299 adults with heart disease: heart attack, stroke or cardiovascular death in 12.1% on tirzepatide against 13.0% on dulaglutide, an older weekly GLP-1 drug with proven heart benefit (hazard ratio 0.92). That met the bar for no worse, not for better 6 8 |
| Obstructive sleep apnea | Zepbound label (December 2024) | SURMOUNT-OSA, 52 weeks: breathing pauses and shallow breaths per hour of sleep fell by about 25 without CPAP (a mask that keeps the airway open overnight) and 29 with it, against about 5 on placebo 5 |
| Diabetes prevention in prediabetes | Trial only | SURMOUNT-1 at 3 years, 1,032 adults with obesity and prediabetes: 1.3% on tirzepatide developed type 2 diabetes against 13.3% on placebo (hazard ratio 0.07, about 93% lower risk) 12 |
| Heart failure with preserved ejection fraction (a stiff heart that still pumps normally) | Trial only; not approved in the US | SUMMIT, 731 adults with obesity: 38% lower risk of cardiovascular death or worsening heart failure 11 |
| Fatty liver with inflammation (MASH) | Phase 2 trial only | SYNERGY-NASH, 52 weeks: MASH cleared without worse scarring in 44%, 56% and 62% on 5, 10 and 15 mg, against 10% on placebo 13 |
Tirzepatide vs semaglutide, the drug in Ozempic and Wegovy
Tirzepatide came out ahead of semaglutide in both direct trials, SURMOUNT-5 for weight 2 and SURPASS-2 for A1C 4, with similar stomach side effects. Semaglutide has the longer outcome record: in SELECT, as the semaglutide guide sets out, "it lowered the rate of heart attack, stroke and cardiovascular death by 20% in adults with heart disease and overweight or obesity who did not have diabetes." Lilly's own GLP-1 pill is orforglipron (Foundayo), and the retatrutide vs semaglutide comparison covers the triple-hormone drug in trials.
Tirzepatide vs semaglutide, head to head
Related medicines
Tirzepatide dosage: the 2.5 mg start and step-ups
Both labels start low on purpose, because nausea and vomiting track the dose increases. The prescriber sets the pace, can hold a step longer when side effects are rough, and need not reach the top dose. The table is for reading a prescription, not for setting your own dose.
| Stage | Weekly tirzepatide dose on the label 7 8 |
|---|---|
| Weeks 1 to 4 | 2.5 mg, a starting step and not a treatment dose |
| Weeks 5 onward | 5 mg |
| After at least 4 weeks on a dose | The prescriber may step up by 2.5 mg at a time: 7.5, 10, 12.5 and 15 mg |
| Maintenance | 5, 10 or 15 mg for weight; 10 or 15 mg for sleep apnea; up to 15 mg for type 2 diabetes in adults and up to 10 mg in children 10 and older |
Taking a weekly tirzepatide injection
How long tirzepatide takes to work
- First few weeks: appetite often falls on the 2.5 mg start, before much shows on the scale.
- About 3 months: A1C needs about that long to show the full drop.
- Months 3 to 12: most of the weight comes off in this stretch. In SURMOUNT-1 the average weight curves flattened between about week 60 and week 72 1.
- If the scale has barely moved after 3 to 6 months on a maintenance dose, raise it with the prescriber, who can review the dose, the side effects or another option.
Side effects and how common they are
| Side effect in SURMOUNT-1 1 | Tirzepatide 5 to 15 mg | Placebo |
|---|---|---|
| Nausea | 24.6% to 33.3% | 9.5% |
| Diarrhea | 18.7% to 23.0% | 7.3% |
| Constipation | 11.7% to 17.1% | 5.8% |
| Vomiting | 8.3% to 12.2% | 1.7% |
| Stopped the drug because of side effects | 4.3% to 7.1% | 2.6% |
Like other GLP-1 drugs, tirzepatide's side effects sit mostly in the gut. They are mostly mild to moderate, cluster in the days after a dose increase and ease over the following weeks 1. Resting heart rate rose by 1 to 3 beats a minute on average, and hair loss was reported more often than on placebo, mostly in women 7.
Serious risks and who should not take tirzepatide
- Thyroid: a boxed warning, the FDA's strongest, because tirzepatide caused tumors of the thyroid C-cells (the cells that make the hormone calcitonin) in preclinical studies; whether it does in people is unknown. Anyone with a personal or family history of medullary thyroid cancer or MEN2 (an inherited tumor syndrome) should not take it. Report a neck lump, trouble swallowing or a hoarse voice that lasts 7.
- Allergy and severe gut disease: not for anyone who has had a serious allergic reaction to tirzepatide, and not recommended in severe gastroparesis, a stomach that barely empties 7 8. Swelling of the face, lips or throat or trouble breathing needs 911.
- Pancreatitis and gallbladder disease are listed warnings 7 8. Severe tummy pain spreading to the back, or upper right tummy pain with fever or yellow skin or eyes, needs care the same day.
- Kidneys: vomiting or diarrhea so heavy you cannot keep fluids down can injure the kidneys and needs care the same day 7.
- Low blood sugar: more likely with insulin or a sulfonylurea 8; get help for shakiness, sweating or confusion that does not settle quickly.
- Eyes: in people who already have diabetic retinopathy, a fast drop in blood sugar can briefly worsen it, so it needs watching 8. Sudden loss or dimming of vision in one eye can be NAION, optic nerve damage listed as a warning on both labels, and needs urgent care 7 8.
- Surgery and sedation: a slow stomach raises the risk of breathing in stomach contents under anesthesia, so tell the surgical team 7.
- Pregnancy: the Zepbound label advises stopping once a pregnancy is recognized, so tell the prescriber as soon as you know 7.
Medicines that interact with tirzepatide
- Insulin and sulfonylureas: prescribers often lower those doses when tirzepatide starts, because the combination can cause low blood sugar 8.
- Birth control pills: the slower stomach can reduce how much of a pill is absorbed, so the labels advise switching to a non-oral method, or adding a barrier method such as condoms, for 4 weeks after starting and after each dose increase 7.
- Other pills that need steady levels, such as warfarin: the label advises closer monitoring while the stomach slows 7.
- Other GLP-1 drugs: tirzepatide is not meant to be combined with semaglutide or any other drug in the class 7.
Muscle loss, protein and eating less
Some of the weight lost on tirzepatide is lean tissue, which includes muscle. In a SURMOUNT-1 substudy that measured body composition with DEXA scans, fat mass fell about 34% on tirzepatide against 8% on placebo, and lean mass about 11% against 3% 1, so roughly three quarters of the loss was fat. Resistance training and enough protein help hold on to muscle while appetite is low.
CalculatorProtein calculatorTurns your body weight into a daily protein range, useful when tirzepatide shrinks your appetiteWork it out A much smaller diet also leaves less room for iron- and B12-rich foods, so ferritin and B12 are reasonable to raise with the prescriber, B12 especially alongside metformin, which lowers it over years. Iron deficiency and B12 deficiency list the signs, and the weight loss page covers the wider picture of tests and habits.
Blood tests before and on tirzepatide
A baseline A1C, fasting glucose, lipid panel, liver panel and kidney panel before the first dose make the later changes easy to read. The prescriber decides which ones and when; a common rhythm is a recheck at about 3 months, then every 6 months or as the prescriber sets.
| Result | Usual change on tirzepatide | When to raise it with the prescriber |
|---|---|---|
| A1C and fasting glucose | Down; the A1C change shows within about 3 months 4 | A rising A1C on a steady dose |
| Triglycerides | Down with weight loss 1 | A rise, which is not the expected direction |
| ALT and AST (liver enzymes) | Often fall as liver fat falls 13 | A rise with yellow skin or upper right tummy pain |
| Creatinine and eGFR (kidney filtration) | Usually stable | Creatinine up and eGFR down after vomiting or diarrhea, a sign of dehydration 7 |
| Lipase and amylase (enzymes made by the pancreas) | Often rise with no pancreatitis (see below) | Straight away with severe tummy pain spreading to the back |
| Ferritin and B12 | Can drift down when eating far less | A low result, or new tiredness, pins and needles or breathlessness |
Markers to read on tirzepatide

In the type 2 diabetes trials, average lipase rose 31 to 42% and pancreatic amylase 33 to 38% on tirzepatide, and the label calls the meaning unknown without other signs of pancreatitis 8. A high lipase with no pain is a result to discuss; with severe tummy pain spreading to the back it needs care the same day. When vomiting or diarrhea dries a person out, blood urea nitrogen tends to climb faster than creatinine; the BUN to creatinine calculator shows the ratio.
Two tests often suggested for people on tirzepatide do not track the drug. TSH measures how hard the brain is driving the thyroid gland and says nothing about C-cells, and the labels call routine calcitonin or thyroid ultrasound checks of uncertain value for catching medullary thyroid cancer early 7. A GLP-1 blood test measures the body's own GLP-1 and cannot detect tirzepatide, so it says nothing about whether the drug is working.
What happens when you stop tirzepatide
In SURMOUNT-4, people switched to placebo regained about half the weight they had lost within a year, and their blood pressure, A1C and cholesterol drifted back with it 3. No withdrawal syndrome has been described; appetite tends to return as the drug clears.
In participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented the initial weight reduction.Aronne et al., SURMOUNT-4, JAMA 2024 3
Semaglutide behaves the same way; the semaglutide guide reports that "a year after stopping, people in STEP 1 had regained about two-thirds of the weight they lost." Plan any stop or taper with the prescriber, with A1C and lipids rechecked a few months later; how to read your lipid panel explains each line.
Cost, insurance and compounded tirzepatide
Without coverage, Lilly sells Zepbound vials and KwikPens direct to self-paying patients through LillyDirect 14.
| Zepbound dose, LillyDirect self-pay | Price per month, starting at |
|---|---|
| 2.5 mg | $299 |
| 5 mg | $399 |
| 7.5 mg to 15 mg | $449 when each refill is within 45 days; $499 to $699 otherwise |
Compounded tirzepatide is a pharmacy-made copy with no FDA approval, allowed while the drug was in shortage. The FDA declared the shortage over on 19 December 2024, and the grace periods ended on 18 February 2025 for state-licensed pharmacies and 19 March 2025 for larger outsourcing facilities 9. The FDA does not review compounded drugs for safety, effectiveness or quality, and has reports of people needing medical care after wrong doses of compounded semaglutide or tirzepatide, from measuring errors and from doses above the label 10. Tirzepatide sold online as a research peptide is not made for people at all 10.
Citations
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36.
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193-1205.
- Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). N Engl J Med. 2025;393:2409-2420.
- Eli Lilly and Company. Zepbound (tirzepatide) injection, US prescribing information. Revised 11/2026.
- Eli Lilly and Company. Mounjaro (tirzepatide) injection, US prescribing information. Revised 11/2026.
- US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. 2025.
- US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss.
- Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med. 2025;392(5):427-437.
- Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention (SURMOUNT-1, 176 weeks). N Engl J Med. 2025;392(10):958-971.
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med. 2024;391(4):299-310.
- Eli Lilly and Company. Zepbound on LillyDirect: self-pay prices. Accessed 21 November 2026.
- Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918.
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.








